Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 7/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 3/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25361277 | 0.79 | PLA2G2C (0.41) | PLA2G2CCES2USP2HTTCYP1A2 | |
| SCHEMBL14234769 | 0.79 | PLA2G2C (0.41) | PLA2G2CCES2USP2HTTCYP1A2 | |
| SCHEMBL22790487 | 0.79 | ALDH1A1 (0.44) | PLA2G2C | |
| SCHEMBL25361274 | 0.79 | PLA2G2C (0.41) | PLA2G2CCES2USP2HTTCYP1A2 | |
| SCHEMBL16174169 | 0.77 | ALDH1A1 (0.35) | — | |
| SCHEMBL9544161 | 0.77 | PLA2G2C (0.63) | PLA2G2CCES2USP2HTTTLR2 | |
| SCHEMBL9544167 | 0.77 | PLA2G2C (0.63) | PLA2G2CCES2USP2HTTTLR2 | |
| SCHEMBL8206127 | 0.77 | MAPT (0.58) | CYP3A4LPAR5LPAR1LPAR3 | |
| SCHEMBL12642020 | 0.77 | NAAA (0.53) | EPHX1 | |
| SCHEMBL28421813 | 0.77 | CES2 (0.55) | PLA2G2CCES2USP2HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | IPSEN PHARMA S.A.S. (FR) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304403-A1 | METHOD FOR INHIBITING INFLAMMATION and PRO-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE | PROKR1, CCL2, PROKR2 | PLA2G2C 2471/4885CES2 4029/4885USP2 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.